MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway

(2016) Lioubov G. Korotchkina et al.   Aging-US

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo

(2015) Zaowen Chen et al.   NEOPLASIA

Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

(2011) T. Van Maerken et al.   MOLECULAR CANCER THERAPEUTICS

p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma

(2010) L. Chen et al.   CANCER RESEARCH

High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma

(2010) J. Carr-Wilkinson et al.   CLINICAL CANCER RESEARCH

MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response

(2010) M. Petroni et al.   MOLECULAR CANCER RESEARCH

Paradoxical suppression of cellular senescence by p53

(2010) Z. N. Demidenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

(2009) J A Canner et al.   BRITISH JOURNAL OF CANCER

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY